S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:NTGN

Neon Therapeutics (NTGN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free NTGN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$3.07
▼
$3.07
50-Day Range
$2.77
▼
$3.07
52-Week Range
$0.88
▼
$6.25
Volume
N/A
Average Volume
516,108 shs
Market Capitalization
$88.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
NTGN stock logo

About Neon Therapeutics Stock (NASDAQ:NTGN)

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

NTGN Stock News Headlines

April 9, 2024 | seekingalpha.com
BCYC Bicycle Therapeutics plc
February 20, 2024 | investing.com
NTGN_old Historical Data
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
December 22, 2023 | seekingalpha.com
NBCO Neon Bloom, Inc.
March 1, 2023 | theguardian.com
Macbeth review – neon-tinted remix plays like a cinematic thriller
See More Headlines
Receive NTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/02/2020
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NTGN
CUSIP
N/A
CIK
N/A
Web
www.neontherapeutics.com
Phone
617-337-4701
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-79,780,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-199.09%
Return on Assets
-137.14%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
1.58
Quick Ratio
3.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
6.14

Miscellaneous

Outstanding Shares
28,967,000
Free Float
N/A
Market Cap
$88.93 million
Optionable
Not Optionable
Beta
-0.81
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Hugh O'Dowd (Age 54)
    Pres, CEO & Director
  • Dr. Eric S. Lander (Age 62)
    Founder & Director
  • Dr. Yasir B. Al-Wakeel (Age 37)
    Chief Financial Officer
  • Dr. Richard Gaynor (Age 69)
    Pres of R&D
  • Dr. Edward Fritsch Ph.D.
    Founder and Chief Technology Officer

Key Competitors

View All Competitors

NTGN Stock Analysis - Frequently Asked Questions

How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) issued its quarterly earnings data on Monday, March, 2nd. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.03.

What other stocks do shareholders of Neon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include VBI Vaccines (VBIV), Aduro Biotech (ADRO), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Pfizer (PFE), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), T2 Biosystems (TTOO) and Vaxart (VXRT).

When did Neon Therapeutics IPO?

Neon Therapeutics (NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager.

This page (NASDAQ:NTGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
How Biden has already won 2024
Porter & Company